{"id":"c2402","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital yeast infections"},{"rate":"null","effect":"Increased risk of urinary tract infections"},{"rate":"null","effect":"Dehydration"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, C2402 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly effective in treating type 2 diabetes.","oneSentence":"C2402 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:04:33.640Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT06643130","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients With Hypertension and Dyslipidemia","status":"RECRUITING","sponsor":"JW Pharmaceutical","startDate":"2024-12-02","conditions":"Hypertension, Dyslipidemia","enrollment":162},{"nctId":"NCT06754943","phase":"PHASE1","title":"To Evaluate the Safety and PK Characteristics After Co-administration of JW0104 and C2402 and Administration of JW0105","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2025-01-17","conditions":"Healthy","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["NA (Not Applicable)"],"phase":"phase_3","status":"active","brandName":"C2402","genericName":"C2402","companyName":"JW Pharmaceutical","companyId":"jw-pharmaceutical","modality":"Small molecule","firstApprovalDate":"","aiSummary":"C2402 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}